Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2024 · 10-Q
Revenue$5.68M$5.68M−88.1% vs Q1 2023 Net Income-$48.50M-$48.50MN/M vs Q1 2023 EPS Diluted-$0.03-$0.03— vs Q1 2023 Operating Income-$49,261,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$32,052,000N/M Margins · derivedOperating margin-867.6%−871.1 pt vs Q1 2023
Net margin-854.2%−856.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end